DekaBank Deutsche Girozentrale Sells 12,685 Shares of DexCom, Inc. (NASDAQ:DXCM)

DekaBank Deutsche Girozentrale reduced its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 1.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 837,620 shares of the medical device company's stock after selling 12,685 shares during the quarter. DekaBank Deutsche Girozentrale owned 0.21% of DexCom worth $56,743,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in DXCM. Norges Bank purchased a new position in shares of DexCom during the 4th quarter valued at approximately $385,367,000. Woodline Partners LP purchased a new position in shares of DexCom during the 4th quarter valued at approximately $63,338,000. Northern Trust Corp boosted its stake in shares of DexCom by 22.2% during the 4th quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock valued at $322,454,000 after buying an additional 753,857 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of DexCom during the 4th quarter valued at approximately $41,295,000. Finally, GAMMA Investing LLC boosted its stake in shares of DexCom by 5,951.7% during the 1st quarter. GAMMA Investing LLC now owns 499,746 shares of the medical device company's stock valued at $34,128,000 after buying an additional 491,488 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on DXCM. The Goldman Sachs Group began coverage on DexCom in a research note on Friday, May 30th. They set a "buy" rating and a $104.00 price objective on the stock. Mizuho began coverage on DexCom in a research note on Thursday, April 10th. They set an "outperform" rating and a $85.00 price objective on the stock. Barclays raised their price objective on DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research note on Monday, May 5th. Canaccord Genuity Group raised their price objective on DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Finally, Robert W. Baird reduced their price objective on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. Five research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $98.50.

DexCom Stock Up 0.7%

Shares of DXCM stock traded up $0.59 during trading on Thursday, hitting $85.46. 3,669,900 shares of the company were exchanged, compared to its average volume of 4,423,943. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.32 and a current ratio of 1.50. The firm has a market capitalization of $33.51 billion, a price-to-earnings ratio of 63.78, a P/E/G ratio of 1.81 and a beta of 1.44. The business's 50-day simple moving average is $84.01 and its 200 day simple moving average is $79.93. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $117.19.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The business had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same quarter last year, the firm earned $0.32 earnings per share. DexCom's revenue was up 12.5% compared to the same quarter last year. As a group, analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Activity at DexCom

In other DexCom news, Director Nicholas Augustinos sold 3,672 shares of the business's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $82.80, for a total value of $304,041.60. Following the sale, the director owned 33,411 shares of the company's stock, valued at $2,766,430.80. The trade was a 9.90% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Michael Jon Brown sold 10,000 shares of the business's stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $84.28, for a total transaction of $842,800.00. Following the completion of the sale, the executive vice president directly owned 95,602 shares in the company, valued at $8,057,336.56. This trade represents a 9.47% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 27,190 shares of company stock worth $2,281,732. 0.32% of the stock is owned by insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.